









JOB AID: PREP PRODUCT USE CONSIDERATIONS FOR STARTING, CONTINUING, STOPPING, AND USE IRREGULARITIES

STARTING REGIMEN AND TIME TO PROTECTION

This same information applies to clients restarting the product after discontinuation or specified period of non-use

ORAL PrEP 		DAPIVIRINE VAGINAL RING 	LONG-ACTING CABOTEGRAVIR 	LENACAPAVIR 
Group A Client takes 1 pill per day taken for 7 consecutive days	Group B Client takes 2 pills taken together ("loading dose")	Client or provider Inserts DVR according to insertion instructions	Administer two CAB-LA injections 1 month apart (+/- 7 days) according to injection instructions Day 0 <ul style="list-style-type: none">• Provider administers INITIATION INJECTION 1 Month 1 <ul style="list-style-type: none">• Provider administers INITIATION INJECTION 2	Administer multiple doses of oral and injectable LEN, referred to as LEN INITIATION REGIMEN, over two consecutive days: Day 0 <ul style="list-style-type: none">• Provider administers INITIATION INJECTION 1 & INITIATION INJECTION 2 in separate locations, according to injection instructions• Client takes 2 LEN pills, referred to as LOADING PILLS 1 & 2 Day 1 <ul style="list-style-type: none">• Client takes 2 LEN pills, referred to as LOADING PILLS 3 & 4
 Protection begins after 7 consecutive days of use	 Protection begins 2-24 hours after loading dose; loading dose ideally taken closer to 24 hours before sex*		 Protection begins approximately 1 week after INITIATION INJECTION 1	 Protection begins within 1 day of completing INITIATION INJECTIONS 1 & 2 and LOADING PILLS 1 & 2 (Day 0) in the INITIATION REGIMEN

Group A: Cis women, trans women taking gender-affirming hormones, trans men, and anyone using TDF-based oral PrEP to prevent HIV from injecting practices
Group B: Cisgender men and transgender women not taking gender-affirming hormones using TDF-based oral PrEP to prevent sexual acquisition of HIV
*applies whether client using TDF-based oral PrEP continuously or as event-driven regimen

CONTINUING USE AND SUSTAINING PROTECTION AFTER PROTECTION ONSET

ORAL PrEP



Group A

Client takes 1 pill/day for as long as protection is needed, which may be an indefinite period for some, and shorter-term for others

Group B

Client takes 1 pill/day for as long as protection is needed, which may be an indefinite period for some, and shorter-term for others*

DAPIVIRINE VAGINAL RING



Client leaves DVR in place, regardless of timing/frequency of sex (or menstruation) and should not remove it immediately after sex, since protection against HIV rapidly declines after removal. The DVR should only be removed after it has been in place for one month

LONG-ACTING CABOTEGRAVIR



BIMONTHLY: Provider administers **FOLLOW-UP INJECTIONS** every **TWO** months (+/- 7 days) according to injection instructions

LENACAPAVIR



BIANNUAL: Provider administers **FOLLOW-UP INJECTIONS** every **SIX** months/26 weeks (+/- 14 days) according to injection instructions

MISSED DOSES

For all products, clients missing multiple doses or experiencing longer durations of non-use may need to be re-tested for HIV and clinically assessed for PEP indication and AHI suspicion before restarting or continuing PrEP

Client should take missed dose as soon as able, but should not take more than 2 doses on one day

Client should take missed dose as soon as able, but should not take more than 2 doses on one day

If DVR not inserted, insert it as soon as able

For clients who missed a scheduled injection, provider determines whether to Restart or Resume:

If last injection was **INITIATION INJECTION #1**:

- ≤ 2 months elapsed, Resume with **INITIATION INJECTION #2**
- >2 months elapsed, Restart with **INITIATION INJECTION #1**

If last injection was **INITIATION INJECTION #2** or **FOLLOW-UP INJECTION**:

- ≤3 months elapsed, Resume with **FOLLOW-UP INJECTION**
- >3 months elapsed, Restart with **INITIATION INJECTION #1**

For clients who missed a scheduled injection, provider determines whether to Restart or Resume:

- If ≤28 weeks since prior injection, Resume with **FOLLOW-UP INJECTION**
- If >28 weeks since prior injection Restart **LEN** with all doses (oral and injectable) in the **INITIATION REGIMEN**

Group A: Cis women, trans women taking gender-affirming hormones, trans men, and anyone using TDF-based oral PrEP to prevent HIV from injecting practices

Group B: Cisgender men and transgender women not taking gender-affirming hormones using TDF-based oral PrEP to prevent sexual acquisition of HIV

*applies whether client using TDF-based oral PrEP continuously or as event-driven regimen

TO DISCONTINUE USE AND ONGOING CLINICAL MONITORING

ORAL PrEP



Group A

Client continues to take 1 pill/day for 7 additional days after the last day of exposure

Post-discontinuation clinical monitoring not necessary

Group B

Client continues to take 1 pill/day for 2 additional days after the last day of exposure*

Post-discontinuation clinical monitoring not necessary

DAPIVIRINE VAGINAL RING



Provider or client removes DVR according to removal instructions, and protection ends upon removal

Post-discontinuation clinical monitoring not necessary

LONG-ACTING CABOTEGRAVIR



CAB-LA remains in the body for approximately 1 year after last injection (the “tail” period), with levels too low to provide protection in final 10-11 months of the tail

Post-discontinuation quarterly visits throughout tail period recommended for HIV testing and assessment of prevention needs

LENACAPAVIR



LEN remains in the body for approximately 1 year after last injection (the “tail” period), with levels too low to provide protection in final 6 months of the tail

Post-discontinuation quarterly visits throughout tail period recommended for HIV testing and assessment of prevention needs

For Oral TDF-based PrEP:

Group A: Cis women, trans women taking gender-affirming hormones, trans men, and anyone using TDF-based oral PrEP to prevent HIV from injecting practices

Group B: Cisgender men and transgender women not taking gender-affirming hormones using TDF-based oral PrEP to prevent sexual acquisition of HIV

*applies whether client using TDF-based oral PrEP continuously or as event-driven regimen